Return to search

Sterol-based Organogel Drug Delivery Systems

In this work, transparent and rigid organogels suitable for intravitreal drug delivery applications were produced with pharmaceutical/food grade polar and amphiphilic solvents with HLB values ranging from 0-19. Maximum sterol solubility was obtained with solvents with approximately HLB=6. Solvents with high sterol solubility also required higher sterol concentrations to produce a gel. However, the strength of all the organogels increased with increasing sterol concentration. Furthermore, DSC and SAXS data suggest that the structure of all the organogels was similar. An in vitro release of dexamethasone was performed over a 5.5 month period using novel organogel- dexamethasone implants. The release of dexamethasone varied from 2 to 5.5 months (or more) depending on the organogel used for the implant. These multiple-month release in vitro profiles are comparable and/or exceed the release of commercially available and FDA approved dexamethasone delivery system Ozurdex (~2 month dexamethasone release).

Identiferoai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:OTU.1807/42386
Date15 November 2013
CreatorsChung, Oliver
ContributorsAcosta, Edgar
Source SetsLibrary and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada
Languageen_ca
Detected LanguageEnglish
TypeThesis

Page generated in 0.0032 seconds